Ireland· IE-PA-EU/1/23/1741/001-003
Lytgobi 4 mg film-coated tablet
A acalabrutinib product containing futibatinib, registered in Ireland by Taiho Pharma Netherlands B.V..
Checked against HPRA (Ireland) on
Informational only — not a medical device.
The record
At a glance
HPRA (Ireland)- Active substance
- Futibatinib
- Manufacturer
- Taiho Pharma Netherlands B.V.
- Country
- Ireland (IE)
- ATC code
- L01XE51
- ATC class
- Acalabrutinib
- Reimbursed
- Not published by this register
- Source register
- HPRA (Ireland)
- Last checked
- September 28, 2026
Packs & prices · 1
- ie_pa_numberEU/1/23/1741/001-003
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
375 interactions on record for acalabrutinib.
Graded by severity as the source publishes them — 201 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Acalabrutinib · interactions on record
375 records
- 201 severe
- 174 moderate
Most severe, free to view
- OmeprazoleA02BC01severe
- PantoprazoleA02BC02severe
- LansoprazoleA02BC03severe
- RabeprazoleA02BC04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Acalabrutinib in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLYTGOBITaiho Pharma Netherlands B.V., Amsterdam
- SwitzerlandLytgobi 4 mg, FilmtablettenTaiho Oncology Europe GmbH
- FinlandLytgobiTaiho Pharma Netherlands B.V.
- FranceLYTGOBI 4 mg, comprimé pelliculéTAIHO PHARMA NETHERLANDS (PAYS-BAS)
- IcelandLytgobiTaiho Pharma Netherlands B.V.
- NetherlandsLytgobi 4 mg filmomhulde tablettenTaiho Pharma Netherlands B.V.
- PolandLytgobiTaiho Pharma Netherlands B.V.
- BelgiumLytgobi 4 mgTaiho Pharma Netherlands
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc945dad-5144-40e0-9047-c662a77acc3b GET /v1/drugs/dc945dad-5144-40e0-9047-c662a77acc3b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Film-coated tablet",
"routes": [
"Oral use"
],
"source": "hpra",
"atc_all": [
"L01XE51"
],
"strength": null,
"pa_number": "EU/1/23/1741/001-003",
"substances": [
"Futibatinib"
],
"legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
"market_info": "Unknown",
"authorised_at": "04/07/2023",
"dispensing_status": "Product subject to prescription which may not be renewed (A)",
"registration_status": "AU",
"supply_legal_status": "Supply through pharmacies only",
"interchangeable_code": null
}See everything about acalabrutinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.